Department of Pharmaceutics, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Karnataka State, 576104, India.
Arthur A. Dugoni School of Dentistry, University of the Pacific, San Francisco, CA 94103, USA.
Nanomedicine (Lond). 2023 Nov;18(27):2061-2080. doi: 10.2217/nnm-2023-0247. Epub 2024 Jan 10.
Oral squamous cell carcinoma (OSCC) is an invasive and highly malignant cancer with significant morbidity and mortality. Existing treatments including surgery, chemotherapy and radiation have poor overall survival rates and prognosis. The intended therapeutic effects of chemotherapy are limited by drug resistance, systemic toxicity and adverse effects. This review explores advances in OSCC treatment, with a focus on lipid-based platforms (solid lipid nanoparticles, nanostructured lipid carriers, lipid-polymer hybrids, cubosomes), polymeric nanoparticles, self-assembling nucleoside nanoparticles, dendrimers, magnetic nanovectors, graphene oxide nanostructures, stimuli-responsive nanoparticles, gene therapy, folic acid receptor targeting, gastrin-releasing peptide receptor targeting, fibroblast activation protein targeting, urokinase-type plasminogen activator receptor targeting, biotin receptor targeting and transferrin receptor targeting. This review also highlights oncolytic viruses as OSCC therapy candidates.
口腔鳞状细胞癌（OSCC）是一种具有侵袭性和高度恶性的癌症，发病率和死亡率都很高。现有的治疗方法包括手术、化疗和放疗，其总体生存率和预后都较差。化疗的预期治疗效果受到耐药性、全身毒性和不良反应的限制。本综述探讨了 OSCC 治疗的进展，重点介绍了基于脂质的平台（固体脂质纳米粒、纳米结构脂质载体、脂质-聚合物杂化物、立方脂质体）、聚合物纳米粒、自组装核苷纳米粒、树枝状大分子、磁性纳米载体、氧化石墨烯纳米结构、刺激响应性纳米粒、基因治疗、叶酸受体靶向、胃泌素释放肽受体靶向、成纤维细胞激活蛋白靶向、尿激酶型纤溶酶原激活物受体靶向、生物素受体靶向和转铁蛋白受体靶向。本综述还强调了溶瘤病毒作为 OSCC 治疗候选物。
